Global Chronic Obstructive Pulmonary Disease (COPD) Market Forecast to Reach USD 16.61 Billion by 2033

Introduction

According to Renub Research Latest Report Chronic Obstructive Pulmonary Disease (COPD) market was valued at USD 13.18 billion in 2024 and is expected to grow to USD 16.61 billion by 2033, at a CAGR of 2.60% between 2025 and 2033. This growth is largely fueled by the rising incidence of COPD due to smoking, environmental pollution, and aging populations, along with advancements in treatment modalities, including combination therapies, biologics, and improved drug delivery systems.

COPD is a progressive respiratory disorder characterized by obstruction of airflow, causing shortness of breath, chronic cough, and excess mucus production. The condition includes diseases such as chronic bronchitis and emphysema, which significantly impact quality of life and contribute to morbidity and mortality globally.

As awareness about early diagnosis and treatment rises, healthcare providers, governments, and pharmaceutical companies are investing heavily in COPD management, therapies, and patient education, making this sector a critical component of the global respiratory care market.

Market Overview

COPD management focuses on controlling symptoms, slowing disease progression, and improving lung function. Treatments include:

Drugs: Bronchodilators, corticosteroids, combination inhalers, and biologics

Oxygen therapy: For patients with severe oxygen deprivation

Surgery: Lung volume reduction surgery (LVRS) and lung transplantation

Other interventions: Pulmonary rehabilitation and non-invasive ventilation

Technological improvements, such as smart inhalers and minimally invasive surgical techniques, are enhancing patient outcomes and compliance. Rising international awareness, coupled with growing cases due to pollution and aging populations, positions COPD as a key focus area in global healthcare initiatives.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Key Market Drivers

1. Rising Prevalence of COPD

COPD is a major public health challenge globally:

According to the World Health Organization (WHO), COPD is the fourth leading cause of death, accounting for 3.5 million deaths in 2021 (~5% of global deaths).

Smoking contributes to over 70% of COPD cases in high-income nations, and 30–40% in low- and middle-income countries, with household air pollution also being a significant factor.

Aging populations increase vulnerability, as older adults are more prone to chronic respiratory diseases.

The increasing number of diagnosed cases fuels demand for effective treatment solutions, boosting the market for both drugs and advanced therapies.

2. Advancements in Treatment Options

Innovations in COPD management are key growth drivers:

Combination inhalers and biologics provide enhanced symptom control and reduced exacerbations.

Smart inhalers improve patient compliance by tracking usage and medication adherence.

New drug approvals, such as Ohtuvayre (a dual PDE3/PDE4 inhibitor) in October 2024, dilate airways and reduce inflammation, offering promising therapeutic benefits.

Minimally invasive procedures like endobronchial valves and lung volume reduction surgery improve outcomes and recovery times.

These advancements allow pharmaceutical companies to develop longer-lasting, more effective therapies, addressing unmet medical needs and expanding patient adoption.

3. Government and Healthcare Initiatives

Governments and healthcare organizations are actively promoting COPD awareness, early diagnosis, and treatment access:

Public health campaigns, smoking cessation programs, and air quality improvement measures reduce disease burden.

Regulatory approvals, reimbursement policies, and healthcare investments enhance access to advanced therapies.

Example: AstraZeneca Pharma India received DCGI approval to market Breztri Aerosphere, a triple-combination inhalation therapy, in January 2025.

These initiatives, particularly in emerging economies, are creating new market opportunities for pharmaceutical companies and medical device manufacturers.

Challenges in the COPD Market

1. High Treatment Costs

COPD treatment, including medications, oxygen therapy, and advanced surgeries, can be expensive:

Many patients, especially in emerging economies, cannot afford proper treatment due to inadequate healthcare coverage.

Out-of-pocket expenses limit access to advanced therapies, slowing market expansion.

2. Underdiagnosis and Low Awareness

COPD is often diagnosed at advanced stages due to:

Low awareness among patients and healthcare professionals

Misconceptions about early symptoms, such as mild cough or shortness of breath

Lack of standardized screening programs

Delayed diagnosis leads to poorer outcomes and restricts overall market growth.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Segment Analysis

By Type

Chronic Bronchitis: Chronic inflammation of the airways; prevalent among smokers and industrial workers.

Emphysema: Damage to alveoli reduces oxygen exchange; therapies include bronchodilators, corticosteroids, and oxygen therapy.

By Treatment Type

Drugs: Bronchodilators, corticosteroids, combination inhalers, and biologics

Oxygen Therapy: Supplemental oxygen for severe COPD

Surgery: LVRS and lung transplantation for advanced cases

Others: Pulmonary rehabilitation, non-invasive ventilation

By Distribution Channel

Hospital Pharmacies: Provide immediate access for inpatients and emergency care

Retail Pharmacies: Widely available and accessible for outpatient use

Online Pharmacies: Convenient, home delivery services, telemedicine integration, and patient adherence support

Regional Insights

North America

The US has a high prevalence of COPD, driven by smoking and air pollution.

Advanced healthcare infrastructure, insurance coverage, and biologics adoption boost market growth.

Example: FDA approved Dupixent (dupilumab) in September 2024 for adults with inadequately controlled COPD with an eosinophilic phenotype.

Europe

France, Germany, Italy, Spain, the UK, Belgium, Netherlands, and Turkey drive the European market.

Government-funded healthcare, smoking cessation programs, and advanced inhalers support growth.

Example: EMA approved Dupixent (dupilumab) in July 2024 as add-on maintenance therapy for uncontrolled COPD.

Asia Pacific

Markets in China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, and New Zealand are expanding.

Rising air pollution, biomass fuel exposure, and smoking prevalence increase COPD incidence.

Example: Lupin Limited launched Vilfuro-G®, the world’s first fixed-dose triple combination drug for COPD in India, November 2023.

Middle East & Africa

Saudi Arabia, UAE, and South Africa are key markets.

Government investments, telemedicine, and online pharmacies enhance drug access and patient compliance.

Example: EVA Pharma implemented strategies in September 2024 to improve asthma and COPD care in Saudi Arabia.

Latin America

Brazil, Mexico, and Argentina show steady growth due to rising awareness, improved healthcare access, and increased COPD prevalence.

Competitive Landscape

Leading companies focus on R&D, new product approvals, and expanding global footprints:

AstraZeneca – Combination inhalers and biologics

Pfizer, Inc. – Innovative COPD drug therapies

GlaxoSmithKline plc. – Bronchodilators, corticosteroids, and combination inhalers

Novartis AG – Biologics and pulmonary care innovations

Astellas Pharma Inc. – Advanced respiratory therapeutics

Abbott Laboratories – COPD drugs and medical devices

Boehringer Ingelheim International GmbH – Inhalers and oxygen therapy devices

Almirall – COPD and chronic respiratory disease treatments

These companies invest in research, technological innovation, and market expansion, enabling enhanced treatment options, improving patient outcomes, and increasing adoption of therapies globally.

Future Outlook

The COPD market is expected to maintain steady growth due to:

Rising prevalence of chronic respiratory diseases due to smoking, pollution, and aging

Continued advancements in pharmacological therapies, biologics, and inhaler technologies

Government initiatives and public health campaigns promoting early diagnosis and treatment

Expansion of online pharmacies and telemedicine improving access to treatment

Development of minimally invasive surgeries and pulmonary rehabilitation programs

With increasing patient awareness, improved healthcare infrastructure, and innovation in therapies, the global COPD market is poised to improve patient outcomes, reduce disease burden, and strengthen the respiratory care ecosystem.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.